We're delighted to announce the launch of our latest troponin product: the recombinant chimeric human Cardiac Troponin binary Complex (Cat. # 8IFC20). This unique complex features the most stable part of cTnI (fragment 28-110) linked with TnC by a 20-aar flexible linker of the cTn I – C complex.
In the 2018 article by Katrukha et al., researchers identified cTnI fragments and calculated their ratio in the blood of patients following acute myocardial infarction (AMI). The study also noted that the region approximately between aar 20-110 of cTnI was characterized as the most stable part of the molecule. Currently, most diagnostic systems employ antibodies with epitopes located in the central part of cTnI. Given that the majority of cTnI molecules in the blood exist in complex with TnC and cTnT, a key advantage of our new product is that the antigen closely mirroring the form found in AMI blood samples. Moreover, the preserved tertiary structure of the chimeric complex guarantees that the antibody binding sites remain unchanged. The high cTnI stability makes this troponin complex an ideal choice for the preparation of a cTnI calibrator and standards. For those who utilize antibodies specific to region 28-110, our new product stands as a compelling alternative either as a standard or calibrator to other two products HyTest offers (Cat. # 8ITCR, Cat. # 8ICR3). Furthermore, according to our internal testing result with antibody pairs of 19C7cc + M155cc – RecChim20C6 + 7B9cc, 8IFC20 demonstrates stable immunoreactivity in two-step sandwich assay.
A foundational element of our triumph in this field is the deep-rooted expertise and commitment of HyTest scientists. With a specialization in cardiac troponin I spanning over two decades, our in-depth understanding of cardiac Troponin I is unmatched. We warmly invite you to explore this new option of recombinant cardiac troponin complex.
Recombinant cardiac troponin ITC and IC complexes TechNotes
HyTest Articles: Katrukha IA, et al. (2018) Full-Size Cardiac Troponin I and Its Proteolytic Fragments in Blood of Patients with Acute Myocardial Infarction: Antibody Selection for Assay Development. Clin. Chem. 2018 Jul;64(7):1104-1112. doi: 10.1373/clinchem.2017.286211. Epub 2018 Apr 9.